Compounds and uses thereof for the modulation of hemoglobin
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
1. A compound of Formula (IIA):
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein
ring A is a 4-10 membered cycloalkyl or 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heterocycle is saturated or contains one double bond, and each heteroatom is independently selected from the group consisting of O, N, S, and oxidized forms of N and S; wherein the cycloalkyl and heterocycle are each optionally substituted with 1 to 5 substituents independently selected from halo and C 1 -C 6 alkyl;
ring B is a 6-membered heteroaryl having 1-2 nitrogen atoms, or an oxidized form thereof, wherein the heteroaryl is optionally substituted with 1-3 substituents independently selected from halo and C 1 -C 6 alkyl;
is a single or a double bond;
R 5 is hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
each R 6 independently is halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl-S(O)—, or C 1 -C 6 alkyl-S(O) 2 —, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo; or a 4-10 membered cycloalkyl or heterocyclyl substituted with an R′R′N— moiety wherein each R′ is independently C 1 -C 6 alkyl or hydrogen; and
p is 0, 1, 2,or 3.
2. The compound of claim 1 , wherein p is 0.
3. The compound of claim 1 , wherein ring A is a 5 or 6 membered heterocycle, wherein the heterocycle is saturated or contains one double bond, and wherein the heterocycle is optionally substituted with 1-3 substituents selected from halo and C 1 -C 6 alkyl.
4. The compound of claim 1 , wherein ring B is pyridinyl optionally substituted with 1-3 substituents independently selected from halo and C 1 -C 6 alkyl.
5. A composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
6. A method for treating sickle cell disease, the method comprising administering to a subject in need thereof a compound of claim 1 .
7. The compound of claim 1 , wherein R 5 is hydrogen, and p is 0.
8. The compound of claim 1 , wherein ring B is pyridinyl.